Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

CLLS has been the topic of a number of other research reports. JMP Securities restated a “market outperform” rating and set a $6.00 target price on shares of Cellectis in a report on Friday, May 31st. Oppenheimer cut their price objective on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 12th.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $2.34 on Wednesday. The business has a 50-day moving average of $2.18 and a two-hundred day moving average of $2.43. The firm has a market capitalization of $130.07 million, a PE ratio of -1.81 and a beta of 3.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a 12 month low of $0.96 and a 12 month high of $3.77.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. The firm had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. As a group, research analysts forecast that Cellectis will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in Cellectis during the 2nd quarter valued at $29,000. Principal Financial Group Inc. boosted its position in Cellectis by 6.2% in the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock valued at $1,125,000 after buying an additional 24,906 shares during the last quarter. Baillie Gifford & Co. grew its stake in shares of Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after acquiring an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC increased its position in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.